SLENDACOR® Weight Management Complex

Research That Builds Trust With Customers

SLENDACOR has been studied in three human clinical trials to date – along with multiple preclinical studies. The design and results of this research offer a range of significant opportunities for your weight management product messaging. Study participants included both men and women. Subjects were of a broad age range and included a healthy population of overweight, not obese, individuals, adding confidence to results in the general population. Calorie-burning effects were seen on the first day of study. Significant weight loss was seen on Day 14, continuing throughout the duration of the study. The research shows statistically significant slimming—with a reduction in waist circumference and no reduction in lean body mass. Serum lipids and the Visceral Adiposity Index improved. In a 2021 study, calorie-burning effects were seen on the first day and the mood of study participants improved.

Clinical Science Demonstrates Weight Loss, Body Shaping, Calorie Burning and Enhanced Metabolism

Slendacor has been studied in three human clinical trials to date and multiple pre-clinical studies. A 2018 16-week double-blind, placebo-controlled study of Slendacor set new standards for communicating efficacy to consumers and regulatory agencies in the weight management category – because of its size, its length, its use of healthy, non-obese men and women, its design and execution. Consistent body weight reductions were observed throughout the 16-week trial – starting with statistically significant weight loss at two weeks. Participants averaged a total weight loss of nearly twelve pounds by the end of the study. The subjects taking Slendacor lost two inches in waist circumference and had no reduction in lean body mass. 

New Studies Shows Thermogenic Benefits and Enhanced Metabolism

Two recent pre-clinical studies on energy expenditure showed that the mechanisms of action are related to the effect of Slendacor on white adipose tissue increasing UCP1 expression to resemble what occurs in more metabolically active brown adipose tissue. The 2021 human clinical trial (manuscript in development) was undertaken to further understand the thermogenic effects of Slendacor in human subjects.

A 2022 human clinical study (awaiting publication) focused on a single daily dose of Slendacor and its effects on resting metabolic rate. Participants using Slendacor showed up to a 15.2% increase in resting energy expenditure (REE) at Day 7. REE and calorie burning increased significantly from baseline on Day 1 of the study. The study also measured heart rate, blood pressure and mood. At no point during the study did heart rate or blood pressure increase in the Slendacor group, indicating there was no stimulant activity – unlike many other thermogenic ingredients. 

The new data on lipolysis shows that Slendacor is not just breaking fat down but increasing the metabolism of that fat and changing the metabolic activity of those fat cells. It is burning fat rather than sending it to energy reserves. These new studies help understand Slendacor as an integral part of a holistic health management program, one that includes body weight management, but in the greater context of cardiometabolic health.

Mood and Psychological Well-being

The Profile of Mood States (POMS) is a psychological rating scale used to assess mood states. In clinical trials, participants taking Slendacor reported improvements in their POMS scores, indicating better mood and psychological well-being. This enhancement in mood can be attributed to the overall health benefits and metabolic improvements brought about by Slendacor​​.